OICR (Dr. R. Al-Awar)
oicr.on.ca
Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
ADC-Linker Platform - developing novel cyclic and heterocyclic hydrazone-based linkers for antibody-drug-conjugates (ADC), allowing for “tuning” of the drug-release properties of the ADC and optimizing for desired applications,